GlassScriptPhysician profile
Trent Mcdaniel
NPI 1437119989
$642.80
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $162 · 2021: $16.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $191.72 | 2019-2020 | |
| Amgen INC. | $89.82 | 2019-2020 | |
| Allergan, INC. | $67.56 | 2020 | |
| Novo Nordisk INC | $56.71 | 2019 | |
| Shire North American Group INC | $42.94 | 2019 | |
| Lilly USA, LLC | $41.94 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $34.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.08 | 2019 | |
| Abbott Laboratories | $23.54 | 2020 | |
| Vifor Pharma, INC. | $18.26 | 2019 | |
| Genentech USA, INC. | $16.97 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.68 | 2019 | |
| Glaxosmithkline, LLC. | $11.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trent Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.